These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Exempt Terminated||2007-005299-15||A Phase I/IIa Open-label Dose Escalation Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283 in Patients with Intermediate or High-Risk Myelofibrosis.||2008-04-15||not-yet-due|
|Reported results||2012-001574-28||A Phase 2 Study of Hsp90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone||2014-10-16||due-trials|
|Exempt, with results||2012-001575-37||A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC).||not-yet-due|
|Reported results||2012-001576-12||A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer||2016-04-15||due-trials|
|Reported results||2012-003977-24||A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment with Sorafenib||2015-08-20||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2014-001233-89||A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Inte...||2019-06-17||bad-data|
|Listed as ongoing, but also has a completion date||2015-005256-97||A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia||2020-06-01||bad-data|
|Ongoing||2015-005257-12||A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previou...||not-yet-due|
|Other||2016-005039-34||Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas||not-yet-due|
|Ongoing||2017-004603-52||An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies||not-yet-due|
|Ongoing||2018-003395-12||A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelom...||not-yet-due|